Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.
about
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisAntibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationOral anti-pseudomonal antibiotics for cystic fibrosisAntibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbationAntibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisOral anti-pseudomonal antibiotics for cystic fibrosisCellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosaAnimal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and DivergencesPseudomonas aeruginosa inhibits endocytic recycling of CFTR in polarized human airway epithelial cellsThe Pseudomonas aeruginosa lipid A deacylase: selection for expression and loss within the cystic fibrosis airway.Aminoglycoside antibiotics induce bacterial biofilm formationRespiratory infection rates differ between geographically distant paediatric cystic fibrosis cohortsBinding of Pseudomonas aeruginosa AlgZ to sites upstream of the algZ promoter leads to repression of transcription.Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'Comparisons of resistance of CF and non-CF pathogens to hydrogen peroxide and hypochlorous acid oxidants in vitroUse of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infectionsGenetic variation and clinical heterogeneity in cystic fibrosisCystic fibrosis: exploiting its genetic basis in the hunt for new therapiesEarly childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection.Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophilsInhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety.Alveolar inflammation in cystic fibrosis.Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth.A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.Breath sulfides and pulmonary function in cystic fibrosisState of progress in treating cystic fibrosis respiratory disease.Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposuresEstrogen aggravates inflammation in Pseudomonas aeruginosa pneumonia in cystic fibrosis mice.Clinical significance of microbial infection and adaptation in cystic fibrosis.Expression of S100A8 correlates with inflammatory lung disease in congenic mice deficient of the cystic fibrosis transmembrane conductance regulator.Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.Clinical and genetic aspects of primary ciliary dyskinesia/Kartagener syndrome.Management of refractory Pseudomonas aeruginosa infection in cystic fibrosisMulticenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints.Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling.Interleukin-10 inhibits elevated chemokine interleukin-8 and regulated on activation normal T cell expressed and secreted production in cystic fibrosis bronchial epithelial cells by targeting the I(k)B kinase alpha/beta complexMolybdate transporter ModABC is important for Pseudomonas aeruginosa chronic lung infectionChronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets.
P2860
Q24188054-CC7A5216-BDB0-450C-898F-AC527961074CQ24198135-924D5DDD-797F-4544-9800-989536EF934AQ24202879-E25E1A53-DA3F-4247-A8F8-C4698A597CC5Q24234854-845BA4A8-5D12-425B-AAD7-2F8C0BD2AE3DQ24240388-8ACA7B1D-A239-496C-A9E2-6E02EC575929Q24243916-322FBC47-91AD-4E03-A79E-778B492D10F7Q26471106-5034E24D-CFD3-4FC0-ADD3-DC8E582AA2E9Q26741599-3F0C7FCF-BE72-41D2-9E18-34005B4F0A43Q26747210-4BF80B65-8DA4-4853-A96B-861DAE0540FAQ28492469-16C19B7A-2E10-4A65-9736-AF89AD26B7AFQ28492613-2515A9FD-E220-4A51-8D66-1F9AB3344122Q28493241-F4C928FF-DE3A-46C9-A205-6C971CDCC7B4Q28589362-CFB4B685-23AC-4CD0-97AC-92AECA6C1A92Q29346781-BA423CA4-096A-4FCE-B4DF-6CC02F90472CQ30413773-02341691-58C9-49EF-92B3-151B9A8B3D7BQ30436229-52F9F8E1-1DD5-4FED-BCFA-7BBEF8C7E06EQ31014143-FC19B62F-26A3-45ED-A010-F8DDD59E2D3AQ31137212-D72E3784-6FD0-4638-A935-DB42CFDA897EQ33645546-F99DF395-4D43-4A9E-9969-AADB4A540A3AQ33664918-F8B1F6C4-5765-49CD-8ADF-953938136BC2Q33688123-5097E5C4-1125-4618-BE5C-36F5FA54BAB8Q33788110-795C85CF-906E-4C71-B518-568EA524A70FQ33834505-0001A7F9-321E-4C2E-8F12-492B15DAB856Q33905883-CB4E47E0-5A8E-4AE9-BFA3-D4D189FBF579Q33929671-9A1689ED-799B-435E-AF98-91A8ECA11EE2Q34047949-8E6B7841-629E-495A-81EE-B925E78079B8Q34116010-4469F87E-46D6-4DE3-82F3-8268E5EB45EFQ34375926-F51760A6-A1F9-4FD7-8FE8-0E9D61274CA2Q34388328-75737459-7E65-42CE-9D93-9E0840135F62Q34426614-C4FE2B8B-9CC1-4EBF-8240-EBC5E352DFA0Q34491552-95E46E24-D400-482A-9B11-498495089A16Q34590648-074BDB1A-7940-4F41-ADB7-FF11E347CB37Q34596738-8E813A86-E8FD-4709-BBE6-F7A2931E2477Q34609964-EAA83273-9B70-4BC3-A90C-5181D72AE384Q35026630-E7B3BDC8-7283-47FF-8209-6BED3DB0E04BQ35173510-B85411AF-401C-4D12-BE86-A118787E93C7Q35638889-7B47463E-B55B-4636-B24F-5C311C220CB1Q35748847-F707B10C-B91B-464B-8F8B-17EF733EED41Q35892115-CEFBD6EB-F31C-4943-9BE4-BA1EDF445576Q35917498-B65EBE6F-C090-4AE2-94DA-96D332EE02AC
P2860
Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Early pulmonary infection, inf ...... infants with cystic fibrosis.
@en
type
label
Early pulmonary infection, inf ...... infants with cystic fibrosis.
@en
prefLabel
Early pulmonary infection, inf ...... infants with cystic fibrosis.
@en
P2093
P356
P1476
Early pulmonary infection, inf ...... infants with cystic fibrosis.
@en
P2093
McNamara S
P304
P356
10.1002/PPUL.1144
P577
2001-11-01T00:00:00Z